Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 17, 2018
Pharmacy Choice - Pharmacy News - July 17, 2018

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
7/17/18 - U.S. Approves New Drug To Treat Smallpox To Counter Risk Of Bio-Terrorism [Daily Independent (Nigeria)]
The U.S. Food and Drug Administration has approved the new drugâ?? tecovirimatâ?? to treat smallpox, the first drug against the deadly disease since a huge vaccination campaign over three decades ago. â??To address the risk of bio-terrorism, Congress has taken steps to enable the development and approval of countermeasures to thwart pathogens that
ABBOTT PARK- Abbott today announced it received approval from the U.S. Food and Drug Administration for a next-generation version of its leading MitraClip heart valve repair device used to repair a leaky mitral valve without open-heart surgery. Abbott received CE Mark for the next-generation device earlier this year, allowing for sale of the device
7/16/18 - Acron Medical Announces FDA 510(k) Clearance of its Signature PEEK TLIF Interbody System, the ACRON Interbody.
Acron Medical, LLC, part of the spineMED Group, is a spine technology organization, dedicated to developing and commercializing globally innovative spinal implants. The company is proud to announce that it has received 510 clearance from the FDA for its signature new technology, the ACRON TLIF Interbody system. Andreas Bernegger, Acron Medical's Co
7/16/18 - Aucta Receives its First Product Approval and Launches Vigabatrin for Oral Solution Under the Brand Name Vigadroneâ?¢
--Aucta Pharmaceuticals, Inc. announced today that it has begun shipping Vigabatrin for Oral Solution, USP, 500 mg, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Aucta's commercial partner Upsher-Smith Laboratories, LLC will launch vigabatrin for oral solution under the brand name Viga
7/16/18 - Braeburn Announces PDUFA Date for CAM2038 for the Treatment of Opioid Use Disorder
PLYMOUTH MEETING, Pa., July 16, 2018/ PRNewswire/-- Braeburn announces that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act goal date of December 26, 2018 for its New Drug Application for CAM2038, an investigational buprenorphine flexible-dose weekly and monthly subcutaneous depot injection for the treatment of a
7/16/18 - Calcitriol New Contract Manufacturing Submission Receives FDA Approval and Allows Rockwell Medical Commercialization of Calcitriol
--Rockwell Medical, Inc. today provided an update regarding Calcitriol, the Company's FDA approved active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. On July 11, 2018, Rockwell Medical received FDA approval of its Prior Approval Supplement for manufacturing Calcitriol. As previously announced,

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement